Tags: MS | drug | ofatumumab | multiple | sclerosis | brain | lesions

MS Drug Shows Promise in Trials

Friday, 11 Oct 2013 08:24 AM

Danish biotech firm Genmab on Thursday announced positive results from a phase II study of its multiple sclerosis drug candidate ofatumumab.
 
In a randomized study of 232 patients with relapsing-remitting multiple sclerosis, treatment with ofatumumab significantly reduced the cumulative number of new brain lesions, the company said.

Relapsing-remitting multiple sclerosis is the most common form of multiple sclerosis, which is an inflammatory disease of the central nervous system.

"We are encouraged by the results from this study," Genmab's chief executive Jan van de Winkel said in the statement.

There were no unexpected safety findings in the study, Genmab said.

Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and Britain's GlaxoSmithKline Plc. Ofatumumab is sold under the name Arzerra for the treatment of blood cancer.

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Danish biotechfirm Genmab on Thursday announced positive results from a phase II study of its multiple sclerosis drug candidate ofatumumab. In a randomized study of 232patients with relapsing-remitting multiple sclerosis, treatment with ofatumumab significantly reduced the...
MS,drug,ofatumumab,multiple,sclerosis,brain,lesions
128
2013-24-11
Friday, 11 Oct 2013 08:24 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved